Treatment of Tuberculous Meningitis

Introduction to Treatment

• The American Thoracic Society recommends initiating immediate empiric four-drug anti-tuberculosis therapy with isoniazid, rifampin, pyrazinamide, and ethambutol for 2 months, followed by isoniazid and rifampin for an additional 7-10 months, plus adjunctive dexamethasone for all patients regardless of disease severity 1, 2

Standard Four-Drug Regimen

• The standard intensive phase regimen includes isoniazid, rifampin, pyrazinamide, and ethambutol, with pyrazinamide dosing per weight 1, 2
• The continuation phase consists of isoniazid and rifampin only after completing the 2-month intensive phase, with a total treatment duration of 9-12 months minimum for CNS tuberculosis 1, 2

Adjunctive Corticosteroid Therapy

• The American College of Chest Physicians strongly recommends dexamethasone dosing for all patients, with adults and children ≥25 kg receiving 12 mg/day for 3 weeks, then tapering gradually over the following 3 weeks 1, 2
• Corticosteroids improve survival and reduce neurological sequelae, with the greatest benefit in patients with altered consciousness 1, 2

Monitoring and Follow-Up

• Repeated lumbar punctures should be performed to monitor CSF cell count, glucose, and protein changes, especially during early treatment 1, 2
• Monitor for hepatotoxicity, particularly during the first 2 months of treatment 3

Special Populations

• HIV-infected patients should use the same standard four-drug regimen for 9-12 months, avoiding highly intermittent regimens in patients with CD4+ counts <100 cells/mm³ due to risk of rifampin resistance 1, 2, 4
• Pregnant women can use isoniazid, rifampin, ethambutol, and pyrazinamide, but should avoid streptomycin due to congenital deafness 3

Drug-Resistant TB Meningitis

• If multidrug-resistant TB is suspected or confirmed, treatment must include at least 3 drugs to which the organism is susceptible, and never add a single drug to a failing regimen 5
• Consider second-line agents such as fluoroquinolones, linezolid, bedaquiline, or aminoglycosides based on susceptibility testing 3, 5, 6